Literature DB >> 22118630

Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes.

Anne Kaas1, Marie Louise Max Andersen, Siri Fredheim, Philip Hougaard, Karsten Buschard, Jacob Steen Petersen, Carine de Beaufort, Kenneth J Robertson, Lars Hansen, Henrik B Mortensen, Lotte B Nielsen.   

Abstract

OBJECTIVE: Proinsulin is a marker of beta-cell distress and dysfunction in type 2 diabetes and transplanted islets. Proinsulin levels are elevated in patients newly diagnosed with type 1 diabetes. Our aim was to assess the relationship between proinsulin, insulin dose-adjusted haemoglobin A1c (IDAA1C), glucagon-like peptide-1 (GLP-1), glucagon, and remission status the first year after diagnosis of type 1 diabetes.
METHODS: Juvenile patients (n = 275) were followed 1, 6, and 12 months after diagnosis. At each visit, partial remission was defined as IDAA1C ≤ 9%. The patients had a liquid meal test at the 1-, 6-, and 12-month visits, which included measurement of C-peptide, proinsulin, GLP-1, glucagon, and insulin antibodies (IA).
RESULTS: Patients in remission at 6 and 12 months had significantly higher levels of proinsulin compared to non-remitting patients (p < 0.0001, p = 0.0002). An inverse association between proinsulin and IDAA1C was found at 1 and 6 months (p = 0.0008, p = 0.0022). Proinsulin was positively associated with C-peptide (p < 0.0001) and IA (p = 0.0024, p = 0.0068, p < 0.0001) at 1, 6, and 12 months. Glucagon (p < 0.0001 and p < 0.02) as well as GLP-1 (p = 0.0001 and p = 0.002) were significantly lower in remitters than in non-remitters at 6 and 12 months. Proinsulin associated positively with GLP-1 at 1 month (p = 0.004) and negatively at 6 (p = 0.002) and 12 months (p = 0.0002).
CONCLUSIONS: In type 1 diabetes, patients in partial remission have higher levels of proinsulin together with lower levels of GLP-1 and glucagon compared to patients not in remission. In new onset type 1 diabetes proinsulin level may be a sign of better residual beta-cell function.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118630     DOI: 10.1111/j.1399-5448.2011.00812.x

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  6 in total

1.  Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes.

Authors:  A Blasetti; C Di Giulio; S Tumini; M Provenzano; D Rapino; L Comegna; G Prezioso; R Chiuri; S Franchini; F Chiarelli; L Stuppia
Journal:  Pharmacogenomics J       Date:  2016-02-23       Impact factor: 3.550

Review 2.  Combination immunotherapies for type 1 diabetes mellitus.

Authors:  Paolo Pozzilli; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 3.  Partial Clinical Remission of Type 1 Diabetes: The Need for an Integrated Functional Definition Based on Insulin-Dose Adjusted A1c and Insulin Sensitivity Score.

Authors:  Benjamin Udoka Nwosu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

Review 4.  Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis.

Authors:  Chunguang Chen; Christian M Cohrs; Julia Stertmann; Robert Bozsak; Stephan Speier
Journal:  Mol Metab       Date:  2017-07-08       Impact factor: 7.422

5.  Serum C-peptide and osteocalcin levels in children with recently diagnosed diabetes.

Authors:  Omaima M Sabek; Maria J Redondo; Duc T Nguyen; Christine A Beamish; Daniel W Fraga; Christiane S Hampe; Surya N Mulukutla; Edward A Graviss; A Osama Gaber
Journal:  Endocrinol Diabetes Metab       Date:  2019-11-29

6.  Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual β-cell function 1 year after diagnosis of type 1 diabetes.

Authors:  Marie Louise Max Andersen; Morten Arendt Rasmussen; Sven Pörksen; Jannet Svensson; Jennifer Vikre-Jørgensen; Jane Thomsen; Niels Thomas Hertel; Jesper Johannesen; Flemming Pociot; Jacob Sten Petersen; Lars Hansen; Henrik Bindesbøl Mortensen; Lotte Brøndum Nielsen
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.